Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition

Area of Science:

• Dermatology
• Oncology
• Genetics

Background:

• Spiradenomas are rare, typically benign skin adnexal tumors often diagnosed in early adulthood.
• The tumor suppressor gene CYLD is implicated in spiradenomas, trichoepitheliomas, and cylindromas.
• Spiradenomas can undergo malignant transformation into aggressive spiradenocarcinomas, with limited reported cases and undefined treatment protocols for metastatic disease.

Purpose of the Study:

• To report the first case of metastatic spiradenocarcinoma managed with PD-1 inhibition therapy.
• To explore the potential of immunotherapy in treating advanced malignant spiradenoma.

Main Methods:

• A single case report of a patient with metastatic spiradenocarcinoma.
• Treatment involved the administration of pembrolizumab, a PD-1 inhibitor.
• Clinical response and outcomes were monitored.

Main Results:

• The patient with metastatic spiradenocarcinoma showed a positive response to pembrolizumab treatment.
• This case demonstrates the efficacy of PD-1 inhibition in managing advanced disease.

Conclusions:

• Pembrolizumab represents a promising therapeutic option for metastatic spiradenocarcinoma.
• Further research is warranted to establish immunotherapy as a standard of care for this rare malignancy.